BW's Seeking Alpha article failed to mention anything regarding:
Today, we have two phase II programs underway #$%$ing AVP-923 (dextromethorphan and quinidine) for the treatment of agitation in Alzheimer's disease and central neuropathic pain in multiple sclerosis (MENTIONED MS PAIN IN THE ARTICLE).
A third program funded by the Michael J. Fox foundation will be initiated shortly to #$%$ AVP-923 for the treatment of levodopa induced dyskinesia in Parkinson's disease.
In addition, we now have a new development program of a next generation asset - AVP-786, or deuterium modified dextromethorphan. A phase I study examining the pharmacokinetic profile of AVP-786 in humans is underway. Finally, we are supporting two investigator-initiated studies testing NUEDEXTA in (1) adult autism and (2) speech and swallowing in patients with ALS (Lou Gehrig's disease).
He does however seem to be back supporting the notion that there may be 2.62222222222222 million patients out there for this drug. I base that on his referring readers back to his and OFP's original prediction. At least the one before they flip flopped into saying that this was barely a 2.00 stock and criticizing my and all our buys in the 2's.
He also seems to have discovered the entire concept of inflation and what it means for this stock and scripts in general whereby out of seemingly nowhere hundreds upon hundreds of scripts can appear on any given monday.
And lastly, he's now of the mindset that breakeven will happen much sooner and SOON..and even very soon we may now see a massive short squeeze.
In OTHER words..he's become a deciple of CONGO.
Actually though, i've decided to go rather easy on him because at LEAST this time he's not writing SA articles bashing my top investments like he did with ALU at 98 cents.